GRIN2B 靶点蛋白|抗体药物|临床药物信息

GRIN2B信息

英文名称：Glutamate [NMDA] receptor subunit epsilon 2
中文名称：谷氨酸[NMDA]受体亚基ε-2
靶点别称：NR2B，hNR3，GluN2B，NMDAR2B，NR3，GRIN2B，Glutamate Ionotropic Receptor NMDA Type Subunit 2B，Glutamate Receptor， Ionotropic， N-Methyl D-Aspartate 2B，Glutamate [NMDA] Receptor Subunit Epsilon-2，N-Methyl D-Aspartate Receptor Subtype 2B，N-Methyl-D-Aspartate Receptor Subunit 3，Glutamate Receptor Subunit Epsilon-2，EIEE27，MRD6，Glutamate Receptor Ionotropic， NMDA 2B

上市药物数量：0
临床药物数量：7
最高研发阶段：临床三期

GRIN2B产品列表

筛选结果

货号	物种	产品描述	蛋白结构	纯度	活性

GRIN2B 分子别名

NMDAR2B

GRIN2B 分子背景

NMDA receptors (NMDARs) are members of the glutamate-gated ion-channel family that mediate a slow calcium-permeable component of excitatory synaptic transmission in the central nervous system. The NMDA receptors are heterotetramers of seven genetically encoded, differentially expressed subunits including NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The early expression of this gene in development suggests a role in brain development, circuit formation, synaptic plasticity, and cellular migration and differentiation.

GRIN2B 前沿进展

GRIN2B临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
S-44858	S-44858	临床一期	Laboratoires Servier	神经变性	详情
Salfaprodil	Neu2000KWL; Neu-2000; Neu-2000KL	临床三期	Global Neurotech	中风	详情
EVT-103	ENS-103; EVT-103	临床一期	罗氏, 强生	重度抑郁症	详情
Ifenprodil (Algernon Pharmaceuticals)	NP-120	临床三期	Algernon Pharmaceuticals Inc	特发性肺纤维化, 冠状病毒感染	详情
BI-1569912	BI-1569912	临床一期	Boehringer Ingelheim Gmbh	重度抑郁症	详情
ALTO-202	ALTO-202	临床二期	Alto Neuroscience Inc	抑郁症, 创伤后应激障碍	详情
MIJ-821	MIJ-821; CAD-9271	临床二期	诺华制药	抑郁, 重度抑郁症	详情

会议日历

会议一览

GRIN2B